Changes of cerebrospinal fluid monoamine metabolites during long-term antidepressant treatment

被引:14
作者
Bäckman, J
Alling, C
Alsén, M
Regnéll, G
Träskman-Bendz, L
机构
[1] Univ Lund, Dept Clin Neurosci, Div Psychiat, Lund, Sweden
[2] Univ Lund, Dept Lab Med, Div Med Neurochem, Lund, Sweden
关键词
antidepressants; cerebrospinal fluid; 5-HIAA; MHPG;
D O I
10.1016/S0924-977X(00)00089-4
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
This study describes the changes in cerebrospinal fluid (CSF) monoamine metabolites during antidepressant treatment for more than 6 months. Eight patients, who received antidepressant treatment after attempted suicide and then underwent lumbar punctures every 3 or 4 months, were included. Plasma drug concentrations and the clinical outcome were also measured. Consistent with previous reports about antidepressant treatment for between 3 and 6 weeks, both 3-methoxy-4-hydroxyphenylethyleneglycol (MHPG) and 5-hydroxyindoleacetic acid (5-HIAA) were significantly decreased after treatment for a mean of 15 weeks compared to pretreatment. However, after continued treatment for a mean of 30 weeks the MHPG concentration remained significantly lower than at pretreatment while 5-HIAA had returned to the pretreatment level. The clinical outcome was significantly correlated to the pretreatment 5-HIAA/MHPG ratio. These results suggest that the frequently reported reduction in CSF 5-HIAA after antidepressant treatment does not remain during long-term treatment. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:341 / 349
页数:9
相关论文
共 26 条
[1]   A DOUBLE-BLIND-STUDY OF ZIMELIDINE, A SEROTONIN UPTAKE INHIBITOR, AND DESIPRAMINE, A NORADRENALINE UPTAKE INHIBITOR, IN ENDOGENOUS-DEPRESSION .2. BIOCHEMICAL FINDINGS [J].
ABERGWISTEDT, A ;
ROSS, SB ;
JOSTELL, KG ;
SJOQUIST, B .
ACTA PSYCHIATRICA SCANDINAVICA, 1982, 66 (01) :66-82
[2]   INTERACTING NEUROTRANSMITTER SYSTEMS - A NONEXPERIMENTAL APPROACH TO THE 5HIAA-HVA CORRELATION IN HUMAN CSF [J].
AGREN, H ;
MEFFORD, IN ;
RUDORFER, MV ;
LINNOILA, M ;
POTTER, WZ .
JOURNAL OF PSYCHIATRIC RESEARCH, 1986, 20 (03) :175-193
[3]  
[Anonymous], 1980, DSM 3
[4]  
ASBERG M, 1973, CLIN PHARMACOL THER, V14, P277
[5]  
ASBERG M, 1986, J CLIN PSYCHIAT, V47, P23
[6]  
ASBERG M, 1978, ACTA PSYCHIAT SCAND, P5
[7]   BIOCHEMICAL EFFECTS OF ZIMELIDINE IN MAN [J].
BERTILSSON, L ;
TUCK, JR ;
SIWERS, B .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1980, 18 (06) :483-487
[8]   CURRENT ADVANCES AND TRENDS IN THE TREATMENT OF DEPRESSION [J].
BLIER, P ;
DEMONTIGNY, C .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1994, 15 (07) :220-226
[9]   EFFECTS OF AMITRIPTYLINE AND IMIPRAMINE ON BRAIN AMINE NEUROTRANSMITTER METABOLITES IN CEREBROSPINAL-FLUID [J].
BOWDEN, CL ;
KOSLOW, SH ;
HANIN, I ;
MAAS, JW ;
DAVIS, JM ;
ROBINS, E .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1985, 37 (03) :316-324
[10]   CEREBROSPINAL-FLUID MONOAMINE METABOLITES IN FLUOXETINE-TREATED PATIENTS WITH MAJOR DEPRESSION AND IN HEALTHY-VOLUNTEERS [J].
DEBELLIS, MD ;
GERACIOTI, TD ;
ALTEMUS, M ;
KLING, MA .
BIOLOGICAL PSYCHIATRY, 1993, 33 (8-9) :636-641